Previous 10 | Next 10 |
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Brooke Story to its...
Sigilon Therapeutics (SGTX) announces the appointment of Philip Ashton-Rickardt as the company's chief scientific officer ((CSO)).Most recently, Ashton-Rickardt served as Senior Vice President for Immunology at AZTherapies.At AZTherapies, he was responsible for preclinical development of cell...
CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced the appointment of Philip Ashton-Ricka...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Tesla (NASDAQ:TSLA) holds a big event next week to showcase its new Model S Plaid, while the tech world will be watching...
CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive ...
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture PR Newswire CAMBRIDGE, Mass. , May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's in...
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening PR Newswire CAMBRIDGE, Mass. , May 19, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet'...
Sigilon Therapeutics (SGTX): Q1 GAAP EPS of -$0.60 misses by $0.01.Revenue of $2.96M (-14.7% Y/Y) misses by $0.54M.Press Release For further details see: Sigilon Therapeutics EPS misses by $0.01, misses on revenue
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the first quarter ...
CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive ...
News, Short Squeeze, Breakout and More Instantly...
Sigilon Therapeutics Inc. Company Name:
SGTX Stock Symbol:
NASDAQ Market:
Sigilon Therapeutics Inc. Website:
NEW YORK, NY / ACCESSWIRE / July 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chase Corporation (NYSE:CCF)'s sale...
NEW YORK, NY / ACCESSWIRE / July 23, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CIRCOR International, Inc. (NYSE: CIR...
NEW YORK, NY / ACCESSWIRE / July 12, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chinook Therapeutics, Inc. (NAS...